Evidence map›Paper›PMID 41162600›Full record

ArticleVirchows Archiv : an international journal of pathology2026

FLCN-mutated eosinophilic renal tumors: clinicopathologic and molecular analysis of five cases highlighting morphologic heterogeneity.

Ming Zhao, Jing Song, Jiayun Xu, Guoqing Ru, Lin Ye, Huizhi Zhang, Suying Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ming ZhaoNingbo Clinical Pathology Diagnosis Center, Ningbo, 315100, China. zhaomingpathol@163.com.ORCID http://orcid.org/0000-0001-5971-7303
Jing SongNingbo Clinical Pathology Diagnosis Center, Ningbo, 315100, China.
Jiayun XuNingbo Clinical Pathology Diagnosis Center, Ningbo, 315100, China.
Guoqing RuCancer Center, Department of Pathology, Zhejiang Province People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, China.
Lin YeDepartment of Pathology, Chain Medical Labs, Hangzhou, 311100, China.
Huizhi ZhangNingbo Clinical Pathology Diagnosis Center, Ningbo, 315100, China.
Suying WangNingbo Clinical Pathology Diagnosis Center, Ningbo, 315100, China.

Funding

Ningbo Top Medical and Health Research Program 2023010211Zhejiang Provincial Medicine and Health Research Foundation 2023KY040Zhejiang Provincial Medicine and Health Research Foundation 2024KY1584
6 · The paper itself

Abstract

Eosinophilic/oncocytic renal cell neoplasms represent a diagnostically challenging group of tumors with overlapping morphologic and immunophenotypic features. Recent advances in molecular genetics have expanded the spectrum of FLCN-mutated renal tumors, including both Birt-Hogg-Dubé (BHD) syndrome-associated and sporadic cases. This study aimed to characterize the clinicopathologic and molecular features of five FLCN-mutated eosinophilic renal tumors, emphasizing their diagnostic pitfalls and heterogeneity. The cohort included three male and two female patients (median age: 61 years) with solitary renal masses (median size: 3 cm), all incidentally detected and managed surgically (partial/radical nephrectomy). All patients lacked clinical stigmata of BHD syndrome (cutaneous fibrofolliculomas, pulmonary cysts) or relevant family history. Histologically, tumors exhibited diverse patterns (solid-nested, tubuloacinar, trabecular) with uniform eosinophilic cytoplasm, low-grade nuclei, hemorrhagic and edematous stroma, and prominent branching dilated vasculature, along with distinctive features such as intraluminal foamy histiocytes, psammomatous calcification, and thyroid follicle-like secretions (all classified as non-conventional FLCN-mutated tumors). None of the cases showed renal oncocytosis in the surrounding renal parenchyma. Immunohistochemically, all cases showed diffuse GPNMB expression, while TFE3 was weakly expressed in one case. Molecular profiling identified pathogenic/likely pathogenic FLCN mutations (truncating mutations in four cases, missense variant in one) without concurrent alterations in TSC1/2, MTOR, FH, SDHx, or MiT family genes. Over a median follow-up of 38 months, no recurrence or metastasis occurred, suggesting an indolent behavior. These findings highlight the morphologic mimicry of FLCN-mutated tumors with a spectrum of renal neoplasms characterized by low-grade eosinophilic features, particularly TSC/MTOR-altered or MiT family renal neoplasms, underscoring the necessity of integrated immunohistochemical (GPNMB) and molecular testing for accurate diagnosis. Despite their heterogeneity, FLCN-mutated tumors typically follow a benign clinical course, though rare aggressive variants warrant vigilance.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsMutationProto-Oncogene ProteinsTumor Suppressor ProteinsAdultAgedDNA Mutational AnalysisFemaleHumansMaleMiddle AgedBiomarkers, TumorFLCN protein, humanProto-Oncogene ProteinsTumor Suppressor ProteinsEosinophilic renal tumorFLCNGPNMBMolecular pathology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.